381 related articles for article (PubMed ID: 16492540)
1. Receptor pharmacology.
Young A
Adv Pharmacol; 2005; 52():47-65. PubMed ID: 16492540
[TBL] [Abstract][Full Text] [Related]
2. Identification of N-terminal receptor activity-modifying protein residues important for calcitonin gene-related peptide, adrenomedullin, and amylin receptor function.
Qi T; Christopoulos G; Bailey RJ; Christopoulos A; Sexton PM; Hay DL
Mol Pharmacol; 2008 Oct; 74(4):1059-71. PubMed ID: 18593822
[TBL] [Abstract][Full Text] [Related]
3. The effects of C-terminal truncation of receptor activity modifying proteins on the induction of amylin receptor phenotype from human CTb receptors.
Udawela M; Christopoulos G; Morfis M; Tilakaratne N; Christopoulos A; Sexton PM
Regul Pept; 2008 Jan; 145(1-3):65-71. PubMed ID: 17884192
[TBL] [Abstract][Full Text] [Related]
4. Deletions of genes encoding calcitonin/alpha-CGRP, amylin and calcitonin receptor have given new and unexpected insights into the function of calcitonin receptors and calcitonin receptor-like receptors in bone.
Lerner UH
J Musculoskelet Neuronal Interact; 2006; 6(1):87-95. PubMed ID: 16675892
[TBL] [Abstract][Full Text] [Related]
5. Distinct receptor activity-modifying protein domains differentially modulate interaction with calcitonin receptors.
Udawela M; Christopoulos G; Tilakaratne N; Christopoulos A; Albiston A; Sexton PM
Mol Pharmacol; 2006 Jun; 69(6):1984-9. PubMed ID: 16531504
[TBL] [Abstract][Full Text] [Related]
6. Multiple ramp domains are required for generation of amylin receptor phenotype from the calcitonin receptor gene product.
Zumpe ET; Tilakaratne N; Fraser NJ; Christopoulos G; Foord SM; Sexton PM
Biochem Biophys Res Commun; 2000 Jan; 267(1):368-72. PubMed ID: 10623626
[TBL] [Abstract][Full Text] [Related]
7. The role of peptides and receptors of the calcitonin family in the regulation of bone metabolism.
Naot D; Cornish J
Bone; 2008 Nov; 43(5):813-8. PubMed ID: 18687416
[TBL] [Abstract][Full Text] [Related]
8. Investigation of CGRP receptors and peptide pharmacology in human coronary arteries. Characterization with a nonpeptide antagonist.
Hasbak P; Saetrum Opgaard O; Eskesen K; Schifter S; Arendrup H; Longmore J; Edvinsson L
J Pharmacol Exp Ther; 2003 Jan; 304(1):326-33. PubMed ID: 12490608
[TBL] [Abstract][Full Text] [Related]
9. Receptor autoradiography as mean to explore the possible functional relevance of neuropeptides: focus on new agonists and antagonists to study natriuretic peptides, neuropeptide Y and calcitonin gene-related peptides.
Dumont Y; Chabot JG; Quirion R
Peptides; 2004 Mar; 25(3):365-91. PubMed ID: 15134861
[TBL] [Abstract][Full Text] [Related]
10. Identification and pharmacological characterization of domains involved in binding of CGRP receptor antagonists to the calcitonin-like receptor.
Salvatore CA; Mallee JJ; Bell IM; Zartman CB; Williams TM; Koblan KS; Kane SA
Biochemistry; 2006 Feb; 45(6):1881-7. PubMed ID: 16460034
[TBL] [Abstract][Full Text] [Related]
11. Amylin receptor phenotypes derived from human calcitonin receptor/RAMP coexpression exhibit pharmacological differences dependent on receptor isoform and host cell environment.
Tilakaratne N; Christopoulos G; Zumpe ET; Foord SM; Sexton PM
J Pharmacol Exp Ther; 2000 Jul; 294(1):61-72. PubMed ID: 10871296
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the human calcitonin gene-related peptide receptor subtypes associated with receptor activity-modifying proteins.
Kuwasako K; Cao YN; Nagoshi Y; Tsuruda T; Kitamura K; Eto T
Mol Pharmacol; 2004 Jan; 65(1):207-13. PubMed ID: 14722252
[TBL] [Abstract][Full Text] [Related]
13. A critical role for the short intracellular C terminus in receptor activity-modifying protein function.
Udawela M; Christopoulos G; Morfis M; Christopoulos A; Ye S; Tilakaratne N; Sexton PM
Mol Pharmacol; 2006 Nov; 70(5):1750-60. PubMed ID: 16912219
[TBL] [Abstract][Full Text] [Related]
14. Functional interaction of G protein-coupled receptors of the adrenomedullin peptide family with accessory receptor-activity-modifying proteins (RAMP).
Born W; Muff R; Fischer JA
Microsc Res Tech; 2002 Apr; 57(1):14-22. PubMed ID: 11921352
[TBL] [Abstract][Full Text] [Related]
15. Adrenomedullin and CGRP interact with endogenous calcitonin-receptor-like receptor in endothelial cells and induce its desensitisation by different mechanisms.
Nikitenko LL; Blucher N; Fox SB; Bicknell R; Smith DM; Rees MC
J Cell Sci; 2006 Mar; 119(Pt 5):910-22. PubMed ID: 16495482
[TBL] [Abstract][Full Text] [Related]
16. Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product.
Christopoulos G; Perry KJ; Morfis M; Tilakaratne N; Gao Y; Fraser NJ; Main MJ; Foord SM; Sexton PM
Mol Pharmacol; 1999 Jul; 56(1):235-42. PubMed ID: 10385705
[TBL] [Abstract][Full Text] [Related]
17. Binding profile of a selective calcitonin gene-related peptide (CGRP) receptor antagonist ligand, [125I-Tyr]hCGRP8-37, in rat brain and peripheral tissues.
Van Rossum D; Ménard DP; Fournier A; St-Pierre S; Quirion R
J Pharmacol Exp Ther; 1994 May; 269(2):846-53. PubMed ID: 8182554
[TBL] [Abstract][Full Text] [Related]
18. The vasorelaxant effect of adrenomedullin, proadrenomedullin N-terminal 20 peptide and amylin in human skin.
Hasbak P; Eskesen K; Lind H; Holst J; Edvinsson L
Basic Clin Pharmacol Toxicol; 2006 Aug; 99(2):162-7. PubMed ID: 16918718
[TBL] [Abstract][Full Text] [Related]
19. Characterization of amylin and calcitonin receptor binding in the mouse alpha-thyroid-stimulating hormone thyrotroph cell line.
Perry KJ; Quiza M; Myers DE; Morfis M; Christopoulos G; Sexton PM
Endocrinology; 1997 Aug; 138(8):3486-96. PubMed ID: 9231803
[TBL] [Abstract][Full Text] [Related]
20. Expression of the calcitonin receptor, calcitonin receptor-like receptor, and receptor activity modifying proteins during osteoclast differentiation.
Granholm S; Lundberg P; Lerner UH
J Cell Biochem; 2008 Jun; 104(3):920-33. PubMed ID: 18384073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
